English | Español
Patient Daily | Apr 16, 2026

FDA urges over 2,200 drug developers to publish clinical trial results
Patient Daily | Apr 16, 2026

FDA approves Filspari as first treatment for rare kidney disease FSGS
Patient Daily | Apr 16, 2026

Patient-centric approach seen as key advantage in drug development, says Parexel executive
Patient Daily | Apr 16, 2026

Lilly announces major investments in China and Japan for oral GLP-1 production
Patient Daily | Apr 16, 2026

Astellas to close Universal Cells’ Seattle office, affecting 50 employees
Patient Daily | Apr 16, 2026

Kailera Therapeutics announces potential $533 million IPO in obesity drug market
Patient Daily | Apr 16, 2026

Johnson & Johnson raises revenue target to $100.8 billion for 2026 after strong first quarter
Patient Daily | Apr 16, 2026

FDA issues draft safety guidance for genome editing therapies on April 14

Trending
+ Regulatory
Patient Daily | Jun 16, 2026

PhRMA official: 'A program meant to help vulnerable patients shouldn't be treated like a business strategy'
+ Regulatory
A. R. Baird | Jun 15, 2026

Health care reform group launches campaign linking consolidation to rising costs
+ Pharmaceuticals
Patient Daily | Jun 16, 2026

Intellia gene editing therapy shows strong results in hereditary angioedema study
+ Pharmaceuticals
Patient Daily | Jun 17, 2026

PwC reports strong biopharma M&A activity as sector shifts to precision science